Premium
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Author(s) -
Tanaka Chiaki,
Yin Ophelia Q. P.,
Smith Tom,
Sethuraman Venkat,
Grouss Karen,
Galitz Lawrence,
Harrell Robert,
Schran Horst
Publication year - 2011
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270010367428
Subject(s) - nilotinib , ketoconazole , pharmacokinetics , cyp3a4 , pharmacology , medicine , tyrosine kinase inhibitor , bioavailability , drug interaction , cyp3a , myeloid leukemia , area under the curve , fluconazole , imatinib , oral administration , cancer , metabolism , cytochrome p450 , antifungal , dermatology
Nilotinib (Tasigna), an orally bioavailable second‐generation BCR‐ABL tyrosine kinase inhibitor, is approved for use in patients with chronic myeloid leukemia in chronic phase and accelerated phase who are resistant or intolerant to prior therapy, including imatinib. Previous in vitro studies indicated that nilotinib metabolism is primarily mediated by CYP3A4. To investigate the effect of CYP3A4 induction and inhibition on nilotinib pharmacokinetics, 2 studies were conducted in healthy volunteers prior to and following treatment with a strong inducer (rifampin) or inhibitor (ketoconazole). In the induction study, administration of rifampin 600 mg once daily for 8 days significantly increased urinary 6β‐hydroxycortisol/cortisol ratio, from a preinduction baseline of 5.8 ± 2.7 to 18.0 ± 10.2 after 8 days of rifampin treatment, confirming an inductive effect on CYP3A4. Nilotinib oral clearance was increased by 4.8‐fold, and the maximum serum concentration (C max ) and area under the serum concentration‐time curve (AUC) were decreased by 64% and 80%, respectively, in the induced state compared with baseline. In the inhibition study, ketoconazole 400 mg once daily for 6 days increased the C max and AUC of nilotinib by 1.8‐ and 3‐fold, respectively, compared with nilotinib alone. These results indicate that concurrent use of strong CYP3A4 inducers or inhibitors may necessitate dosage adjustments of nilotinib and should be avoided when possible.